Triple Artemisinin-based Combination Therapy for Delaying Drug Resistance Development - a Randomized Clinical Trial

NCT05764746 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

384

Enrollment

OTHER

Sponsor class

Conditions

Uncomplicated Plasmodium Falciparum Malaria

Interventions

DRUG: Artemether-lumefantrine and Amodiaquine Drug Combination
DRUG: Artemether-lumefantrine then Artesunate amodiaquine
DRUG: Artemether-lumefantrine

Sponsor

Muhimbili University of Health and Allied Sciences

Collaborators

[object Object]
[object Object]